Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

Others Sign Big Deals With Multinationals

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

Nasdaq
ABL Bio, Other Bioventures Dominate Large Global Deals So Far (Shutterstock)

More from South Korea

More from Business